# Gonadorelin: Evidence, Mechanism, Dosing & Legal Status

> A clinical monograph on gonadorelin — synthetic native GnRH used as an HPG-axis diagnostic and as pulsatile pump therapy. Real human efficacy in narrow indications, but the popular TRT-adjunct use is essentially unstudied.

*Published 2026-06-30 · Updated 2026-07-01 · By Marcus Feld, PharmD, BCPS*

The short answer
Gonadorelin is **synthetic native GnRH (LHRH)**, and its value tracks exactly with how faithfully you reproduce nature's pulse. It is a **validated diagnostic test** (effectively Grade A as a test) and has **decades-deep human efficacy as pulsatile pump therapy** for ovulation induction and male congenital hypogonadotropic hypogonadism — graded **B**. But the now-dominant use, an intermittent-SC TRT adjunct, is essentially unstudied (Grade D).[2](https://peptidevox.com/#r2)[28](https://peptidevox.com/#r28)

Gonadorelin is the exact ten-amino-acid hypothalamic decapeptide that drives the pituitary to release LH and FSH — native gonadotropin-releasing hormone, also called LHRH.[1](https://peptidevox.com/#r1)[2](https://peptidevox.com/#r2) It was once sold for human use as Factrel (a diagnostic) and Lutrepulse (a pump therapy), and it has re-entered the spotlight as a compounded TRT adjunct. This monograph separates what is proven from what is merely popular.

*This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing or buying guide. Gonadorelin is a prescription/diagnostic agent and is prohibited in male sport. Dosing figures are reported strictly as seen in the published literature and historical labeling for completeness — not as recommendations. Consult a licensed clinician before any health decision.*

## What is gonadorelin and how does it work?

Gonadorelin is a decapeptide identical in sequence to endogenous GnRH/LHRH (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2; molecular formula C55H75N17O13, MW approximately 1182 free base), the proteolytic product of a 92-amino-acid precursor, marketed as the hydrochloride (Factrel) or acetate (Lutrepulse) salt.[1](https://peptidevox.com/#r1)[5](https://peptidevox.com/#r5) It binds the GnRH receptor (GnRHR), a seven-transmembrane Gq/11-coupled GPCR on anterior-pituitary gonadotroph cells; binding triggers IP3-mediated calcium release plus voltage-gated calcium influx, driving synthesis and secretion of LH and FSH, which in turn drive gonadal steroidogenesis and gametogenesis.[2](https://peptidevox.com/#r2)[3](https://peptidevox.com/#r3)

The defining pharmacology is pulsatility — an agonist that becomes a suppressant depending on how you deliver it. Endogenous GnRH is secreted in pulses roughly every 60 to 120 minutes; delivered in matching pulses, gonadorelin stimulates physiologic LH and FSH.[2](https://peptidevox.com/#r2) Delivered continuously, or as a long-acting super-agonist analogue such as leuprolide, the same receptor agonism causes GnRHR downregulation and desensitization, collapsing LH and FSH after an initial flare — chemical castration.[4](https://peptidevox.com/#r4)[3](https://peptidevox.com/#r3) Pulse frequency also tunes the LH:FSH ratio (faster favors LH, slower favors FSH).[3](https://peptidevox.com/#r3) Reinforcing this, gonadorelin has an extremely short plasma half-life — on the order of 2 to 4 minutes by some sources — being rapidly hydrolysed to inactive fragments and renally cleared; that rapid clearance is functional, not incidental, because it permits a clean pulse and prevents continuous-exposure desensitization, which is why sustained therapy historically required an infusion pump.[6](https://peptidevox.com/#r6)[7](https://peptidevox.com/#r7)

## What is the evidence by indication?

Gonadorelin's evidence is unusually stratified: a validated diagnostic, two genuinely effective pump therapies, and one popular-but-unproven extrapolation. The table summarizes where each use sits.

  Gonadorelin evidence by indication

    UseBest evidenceGrade

    HPG-axis diagnostic stimulation testValidated LH-response cutoffs; 30-min peak LH cutoff with ~99% sensitivity / 100% specificity in precocious pubertyA-adjacent (diagnostic)
    Ovulation induction (hypothalamic amenorrhea), pulsatile pumpPivotal 109-woman study + 25-year cohort: ~90-96% ovulation per cycle, low OHSSB (human)
    Spermatogenesis in male CHH, pulsatile pumpProspective self-controlled trial + meta-analysis vs gonadotropinsB (human)
    TRT adjunct (anti-atrophy / fertility), intermittent SCNo controlled trial; extrapolation from pump dataD (extrapolation)

The diagnostic use is the original FDA indication. A single 100-mcg bolus with LH/FSH sampling at 0, 30, 60 and 120 minutes distinguishes hypothalamic from pituitary causes of hypogonadism and helps separate constitutional delay of puberty from hypogonadotropic hypogonadism.[1](https://peptidevox.com/#r1)[11](https://peptidevox.com/#r11) Performance is well characterized: a 30-minute peak LH of at least 5 IU/L distinguished central from peripheral precocious puberty with sensitivity 99 percent and specificity 100 percent, while in males a peak LH below about 9.74 IU/L identified hypogonadotropic hypogonadism with sensitivity around 74 to 80 percent and specificity 86 to 91 percent.[12](https://peptidevox.com/#r12)[11](https://peptidevox.com/#r11) Here efficacy means diagnostic accuracy, not treatment.

The two pump therapies are where gonadorelin treats. In a pivotal study of 109 women with hypothalamic amenorrhea, pulsatile gonadorelin produced ovulation in 91 to 96 percent of patients, and a 25-year cohort reported a 96 percent ovulation rate per cycle with 75 percent monofollicular ovulation and low multiple-gestation rates — positioning the pump as safer and more physiologic than injectable gonadotropins.[8](https://peptidevox.com/#r8)[9](https://peptidevox.com/#r9) In male congenital hypogonadotropic hypogonadism, a multicentre prospective self-controlled trial of 28 men showed LH rising from 0.20 to 5.96 IU/L and FSH from 0.53 to 5.51 IU/L by six months, and a systematic review and meta-analysis (7 studies, 420 patients) found pulsatile GnRH associated with earlier spermatogenesis (weighted mean difference -5.30 months) and larger testicular volume versus combined gonadotropins, with no significant difference in overall spermatogenesis rate.[13](https://peptidevox.com/#r13)[14](https://peptidevox.com/#r14) Both indications are real human efficacy against an active comparator — graded B because placebo-RCTs are impractical in anovulatory or azoospermic populations.

Proven vs popular
Proven: the diagnostic test and the two pump therapies. Popular but unproven: the intermittent-SC TRT adjunct that drives most current compounded demand — it rose to prominence chiefly because compounded hCG became legally unavailable after FDA's 2020 enforcement, not because trials showed gonadorelin works in that context.[28](https://peptidevox.com/#r28)

That brings us to the TRT adjunct, the weakest-evidenced and most marketed use. The rationale is sound: exogenous testosterone suppresses LH and FSH, dropping intratesticular testosterone by up to roughly 94 percent and impairing spermatogenesis, and gonadorelin should in principle restore pulsatile LH and FSH — and uniquely, unlike hCG, also drives FSH.[28](https://peptidevox.com/#r28)[29](https://peptidevox.com/#r29) But every controlled gonadorelin study is for pump-delivered pulsatile therapy in diagnosed hypogonadotropic conditions, not for intermittent subcutaneous injections layered on top of TRT, and in a deeply suppressed axis non-pulsatile dosing may not reliably maintain intratesticular testosterone — while excessive or continuous dosing can desensitize the axis, the opposite of the goal.[28](https://peptidevox.com/#r28)[30](https://peptidevox.com/#r30) Grade D: plausible, widely practiced, unproven.

## What doses appear in the literature?

Reported strictly as information, not a protocol. For the diagnostic stimulation test, the literature and historical labeling describe a single 100-mcg subcutaneous or intravenous bolus in adults (60 mcg/m2, max 100 mcg, in children) with LH/FSH drawn at 0, 30, 60 and 120 minutes.[1](https://peptidevox.com/#r1)[11](https://peptidevox.com/#r11) For the ovulation-induction pump (Lutrepulse), a typical starting regimen was about 5 mcg every 90 minutes via subcutaneous or intravenous infusion pump, with response usually within two to three weeks.[8](https://peptidevox.com/#r8)[31](https://peptidevox.com/#r31) For male CHH the pump delivers pulses roughly every 90 to 120 minutes, titrated to LH, FSH and testosterone over months.[13](https://peptidevox.com/#r13) The TRT-adjunct subcutaneous dosing seen in compounding and telehealth practice varies widely (commonly small microgram doses two to three times weekly or more frequently) — this is not derived from controlled trials, and high or continuous dosing risks axis desensitization. The official ClinicalTrials.gov registry of GnRH studies can be browsed at [clinicaltrials.gov](https://clinicaltrials.gov/search?term=pulsatile%20GnRH) for the underlying pump trials.[4](https://peptidevox.com/#r4)

## How safe is gonadorelin?

Most adverse effects are mild: injection-site reactions, headache, light-headedness, flushing, nausea and abdominal discomfort, with local or generalized skin rash possible during chronic subcutaneous use.[16](https://peptidevox.com/#r16)[1](https://peptidevox.com/#r1) The serious risks are rare but real. Hypersensitivity and anaphylaxis — bronchospasm, tachycardia, urticaria, hypotension, syncope — have been reported especially after repeated or multiple-dose administration; a documented case described a man on ten weeks of pulsatile subcutaneous GnRH who developed near-immediate dizziness, hypotension and loss of consciousness after an intravenous dose, so first intravenous exposure should occur where anaphylaxis can be managed, and cross-reactivity across analogues warrants skin testing before switching.[15](https://peptidevox.com/#r15)[17](https://peptidevox.com/#r17) Pituitary apoplexy — hemorrhage or infarction of a pre-existing adenoma — is a rare class risk.[18](https://peptidevox.com/#r18) In ovulation induction, multiple pregnancy runs around 12 percent in pump series with rare OHSS.[8](https://peptidevox.com/#r8) Contraindications include known hypersensitivity to GnRH/LHRH or analogues, pituitary adenoma, and conditions aggravated by rising sex steroids; gonadotropin responses are also altered by spironolactone, oral contraceptives and digoxin, so the diagnostic test should run off interfering drugs.[1](https://peptidevox.com/#r1)

## What is the FDA and WADA status in 2026?

Gonadorelin was FDA-approved for human use — Factrel for HPG-axis diagnostic testing and Lutrepulse for ovulation induction — but both were discontinued for commercial or business reasons, not safety or efficacy.[1](https://peptidevox.com/#r1)[28](https://peptidevox.com/#r28) As of 2026 no FDA-approved human gonadorelin product is commercially marketed in the United States; the only active approved Factrel is a veterinary product for cattle, explicitly not for human use.[1](https://peptidevox.com/#r1) Crucially, gonadorelin acetate is a Category 1 bulk substance on the FDA's interim 503A and 503B compounding lists, meaning the FDA does not intend to take action against compounders using it while evaluation continues; the January 2025 final interim guidance finalized the earlier draft and retained permissible Category 1 substances.[19](https://peptidevox.com/#r19)[21](https://peptidevox.com/#r21) Gonadorelin's Category 1 standing contrasts with the Category 2 restriction of several growth-hormone-secretagogue peptides, and an FDA Pharmacy Compounding Advisory Committee meeting was scheduled for July 23-24, 2026 to review additional peptides.[22](https://peptidevox.com/#r22)[23](https://peptidevox.com/#r23) Net practical position: gonadorelin can be legally compounded by licensed 503A/503B pharmacies and prescribed via telehealth with a valid prescription, while gray-market 'research-chemical' gonadorelin sold without a prescription is not legitimate for human use.[24](https://peptidevox.com/#r24)[32](https://peptidevox.com/#r32)

For sport the rule is sex-specific. Gonadorelin and its agonist analogues are prohibited at all times in males under S2.2.1 (testosterone-stimulating peptides) of the 2026 WADA Prohibited List because they raise endogenous testosterone; GnRH analogues have been listed since January 1, 2016, and metabolites are likewise prohibited.[25](https://peptidevox.com/#r25)[26](https://peptidevox.com/#r26) The same substance is not prohibited in female athletes, and a male athlete with a legitimate medical need would require a Therapeutic Use Exemption.[27](https://peptidevox.com/#r27)

**Bottom line.** Gonadorelin is the real thing — native GnRH — and its value is inseparable from the pulse. Treat the diagnostic test and the pulsatile pump therapies as evidence-backed (B, with the diagnostic effectively A as a test), and treat the intermittent-SC TRT-adjunct use as a reasonable but unproven extrapolation (D), where hCG and enclomiphene currently carry the deeper evidence base. Legally it is unmarketed yet compoundable (Category 1) and telehealth-prescribable, and prohibited in male athletes. Regulatory facts are current as of June 2026; the July 23-24, 2026 PCAC outcome was pending at the time of writing and should be re-verified after that date.

---
Source: https://peptidevox.com/peptide-encyclopedia/gonadorelin
Index: https://peptidevox.com/llms.txt · Full text: https://peptidevox.com/llms-full.txt